Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Jun
08
Today In Oncology
AML All-Oral Regimen Safe and Eases Treatment Administration Burden
Study Identifies Serious Infection Risks Linked to Antibody-Drug Conjugates
Overall Survival With EBRT in Hepatocellular Carcinoma
SCLC With Brain-Only Progression Original or Substitute Systemic Therapy With or Without Brain Radiotherapy
Five-Year Survival Analysis: Neoadjuvant Trastuzumab-Pertuzumab Plus Endocrine Therapy or Chemotherapy in HR-Positive/HER2-Positive Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo